Company: LIMN
Filing Date: 2025-06-02
Form Type: 8-K/A
Source: 0001104659-25-055078
Chunk: 25

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-02
Form: 8-K/A
Chunk 25
---
 over the shares held by Nongae Apple Association 1st is Mary H. Song. The business address 
 of Nongae Apple Association 1st is 42 147-gil (#2707) Unju-ro, Kangnam-gu, Seoul, Republic of Korea.                                     |

<div align='center'>15</div>

| (8) | Consists of shares of ParentCo Common Stock held of record by Red Peony Association 1st. The natural person                             
 who has voting and/or investment power over the shares held by Red Peony Association 1st is Kyung Bok Hyun. The business address of Red 
 Peony Association 1st is 353, Hyoryeong-ro, Seocho-dong, Seocho-gu, Seoul, Republic of Korea.                                           |

Directors and Executive Officers

The Company’s directors
and executive officers after the Closing are described in the Proxy Statement/Prospectus in the section titled “Management of ParentCo Following the Business Combination” beginning on page 207 which is incorporated herein by reference.

The following persons constitute
the executive officers and directors of the Company:

| Name                     |     | Age |     | Title                                |
| Chris Kim                |     |  65 |     | Chief Executive Officer and Director |
| Scott Dam                |     |  46 |     | Chief Financial Officer              |
| Byong C. Yoo, PhD        |     |  53 |     | Chief Science Officer                |
| Sang-jin Daniel Lee, PhD |     |  57 |     | Head of Research & Development       |
| Beom K. Choi             |     |  53 |     | Chief Technology Officer             |
| Eun Sook Lee, MD, PhD    |     |  62 |     | Director                             |
| Nicholas Fernandez       |     |  40 |     | Director                             |
| Ji Yeon Baek             |     |  53 |     | Director                             |

Director and Executive Compensation

Information regarding the
compensation of the named executive officers and directors of the Company before and after the Business Combination is set forth in the
Proxy Statement/Prospectus in the section titled “Executive Officer and Director Compensation” beginning on page 206
of the Proxy Statement/Prospectus, which is incorporated herein by reference.

Committees of the Board

The Combined Company’s
Board has three standing committees: an audit committee, a compensation committee and a nominating